RecruitMe Clinical Trial
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MTAU9937A IN PATIENTS WITH PRODROMAL-TO-MILD OR MODERATE ALZHEIMER'S DISEASE
Efficacy and Safety Study of Drug (MTAU9937A) in Patients with Alzheimer's Disease Preclinical-to-Mild or Moderate Alzheimer's Disease
| Sponsor: | Genentech, Inc. |
| Enrolling: | Male and Female Patients |
| Age Range: | Between 50 and 85 years old |
| IRB Number: | AAAR6047 |
| U.S. Government ID: | NCT03289143 |
| Contact: | Katrina Cuasay: 212-305-2371 / kc2305@cumc.columbia.edu |
Additional Study Information:
This is a Phase II, randomized, double-blind, placebo-controlled, parallel-group study that will evaluate the efficacy, safety and tolerability, pharmacokinetics, and pharmacodynamics of the study drug (an antibody to the tau protein called MTAU9937A) in patients with prodromal or mild Alzheimer's disease. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period.
This study is closed
